Filtered By:
Drug: Dexamethasone
Management: Marketing
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
The European Medicines Agency Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma
Oncologist. 2021 Jul 2. doi: 10.1002/onco.13892. Online ahead of print.ABSTRACTIsatuximab is a monoclonal antibody that binds to the human CD38 antigen. On 30 May 2020, a marketing authorization valid through the European Union (EU) was issued for isatuximab in combination with pomalidomide and dexamethasone (IsaPd) for the treatment of adult patients with relapsed and refractory (RR) multiple myeloma (MM). The recommended dose of isatuximab was 10 mg/kg, administered IV weekly at cycle 1 and then biweekly in subsequent 28-day cycles. Isatuximab was evaluated in a phase 3, open label, multicenter randomized trial that rand...
Source: The Oncologist - July 2, 2021 Category: Cancer & Oncology Authors: Julio Delgado Malgorzata Zienowicz Paula Boudewina van Hennik Alexandre Moreau Christian Gisselbrecht Harald Enzmann Francesco Pignatti Source Type: research
